Insider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Sells 6,028 Shares of Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Thomas Richard Kassberg sold 6,028 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $253,778.80. Following the completion of the transaction, the executive vice president now owns 265,238 shares of the company’s stock, valued at $11,166,519.80. This trade represents a 2.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Ultragenyx Pharmaceutical Stock Down 0.4 %

Shares of NASDAQ RARE traded down $0.16 during trading on Tuesday, reaching $41.10. 1,385,598 shares of the company traded hands, compared to its average volume of 779,217. The firm has a 50 day simple moving average of $42.86 and a 200-day simple moving average of $49.03. The stock has a market capitalization of $3.80 billion, a PE ratio of -6.48 and a beta of 0.60. Ultragenyx Pharmaceutical Inc. has a 52-week low of $37.02 and a 52-week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). The company had revenue of $164.88 million for the quarter, compared to analysts’ expectations of $163.23 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. As a group, research analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on RARE shares. Canaccord Genuity Group upped their price objective on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a report on Tuesday, February 18th. JPMorgan Chase & Co. decreased their price objective on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating for the company in a report on Thursday, November 21st. Cantor Fitzgerald restated an “overweight” rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. Royal Bank of Canada reiterated an “outperform” rating and issued a $77.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. Finally, Wedbush reiterated a “neutral” rating and issued a $48.00 price target (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, Ultragenyx Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average target price of $93.50.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several large investors have recently added to or reduced their stakes in RARE. Smartleaf Asset Management LLC lifted its holdings in Ultragenyx Pharmaceutical by 259.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 493 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new position in Ultragenyx Pharmaceutical during the fourth quarter valued at approximately $35,000. Human Investing LLC purchased a new position in Ultragenyx Pharmaceutical during the fourth quarter valued at approximately $42,000. True Wealth Design LLC bought a new stake in shares of Ultragenyx Pharmaceutical during the third quarter valued at approximately $43,000. Finally, Van ECK Associates Corp raised its position in shares of Ultragenyx Pharmaceutical by 18.4% during the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 273 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.